



Nine-month figures for 2009:

Sales revenue up 8.6%; underlying EBITA up 55.9%

€ in millions	9 month 2009	9 month 2008	Change in %	Change in % (in constant currencies)
Sales revenue	298.7	275.0	+8.6	+6.3
• Europe ¹⁾	173.6	169.5	+2.5	+4.0
• North America ¹⁾	72.5	59.5	+21.9	+9.6
• Asia Pacific ¹⁾	40.5	37.2	+8.8	+4.8
• Other Markets ¹⁾	12.1	8.8	+36.9	+36.8
EBITA ²⁾	46.4	29.8	+55.9	
EBITA margin ²⁾	15.5	10.8		
Net profit ^{2) 3)}	26.5	13.9	+91.6	
Earnings per share (€) ^{2) 3)}	1.55	0.81	+91.6	

¹⁾ Acc. to customers' location

²⁾ Underlying for 2009

³⁾ Excluding amortization

Dynamic growth in all business regions

In the first nine months of 2009, Sartorius Stedim Biotech (SSB) achieved dynamic growth in order intake and sales revenue in all regions of its business, particularly in the U.S. and Asia. Single-use products with their double-digit growth rates contributed overproportionately to these results. In addition to its already positive development, SSB profited from the strong demand in the vaccine industry, especially for disposable bags and filters. Due to market conditions, equipment business with large-scale, reusable bioreactors declined somewhat, but saw positive momentum in the 3rd quarter.

Significantly overproportionate growth in profitability

SSB boosted its nine-month earnings before interest, taxes and amortization and adjusted for extraordinary effects (underlying EBITA) by 55.9% from 29.8 million euros in the year-earlier period to 46.4 million euros. The corresponding EBITA margin rose from 10.8% to 15.5%. Besides the uplift generated by the increase in sales volume, SSB's enhanced product mix favoring high-margin single-use products added to this surge in profitability. Extraordinary effects, which include mainly non operating depreciation, accounted for 1.8 million euros.

Strong financial position

Reflected by an equity ratio of 57.1% and gearing of 0.3, the financial position of the Sartorius Stedim Biotech Group further enhanced its very robust level.

Positive outlook

For the last three months of the current fiscal year, company management expects Sartorius Stedim Biotech's sales revenue to increase and its earnings to rise overproportionately relative to the fourth quarter of 2008.

Sartorius Stedim Biotech S.A.
 Z.I. des Paluds
 Avenue de Jouques
 B.P. 1051
 13781 Aubagne - France
www.sartorius-stedim.com

Press Contact:
 Petra Kirchoff
 Phone +49 (0)551.308.1686

Aubagne | Goettingen,
 October 22, 2009

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call and webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Thursday, October 22, 2009, at 3:00 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 2:45 p.m. CET at the following numbers:

Germany: +49 (0)69 9897 2623

France: +33 (0)1 70 99 42 84

UK: +44 (0)20 7138 0845

USA: +1 212 444 0896

The dial-in code is: 4830253

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.

Contact: Petra Kirchhoff; Vice President of Group Corporate Communications;
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany;
Phone: +49(0)551/ 308-1686; Fax: +49(0)551/ 308-3410;
e-mail: petra.kirchhoff@sartorius.com; <http://www.sartorius-stedim.com>